Fundamentals-based quality & risk · not a recommendation
Raw blend 72 capped to 58 by a red flag.
Raw blend 72 → capped to 58
Gujarat Themis Biosyn Ltd scores 58/100 (Watch) on the Orion Score — strong business quality (80), moderate growth (58) and moderate balance-sheet safety (67). A fundamentals-based quality & risk score, not a buy/sell recommendation.
Risk checks
Forensic accounting
Piotroski F = fundamental health (0–9, higher is better) · Altman Z = bankruptcy / distress risk · Beneish M = earnings-manipulation check
Technical / Momentum
Price Trend
39/100
Technical momentum companion — separate from the fundamentals-based Orion Score.
Unlock with Pro
Upgrade →Q4 FY2026
Revenue & Profit in ₹ Crores
| Quarter | Revenue | Net Profit | OPM | EPS |
|---|---|---|---|---|
| Q4 2026 | ₹44.23 | ₹10.89 | 34.6% | ₹1.00 |
| Q3 2026 | ₹43.37 | ₹12.46 | 40.2% | ₹1.14 |
| Q2 2026 | ₹42.35 | ₹14.26 | 42.5% | ₹1.31 |
| Q1 2026 | ₹35.87 | ₹9.06 | 33.1% | ₹0.83 |
| Q4 2025 | ₹37.74 | ₹12 | 39.2% | ₹1.10 |
Revenue & Profit in ₹ Crores (Yearly)
| Year | Revenue | Net Profit | EBITDA | OPM |
|---|---|---|---|---|
| FY 2025 | ₹150.8 | ₹48.77 | ₹71.55 | 42.1% |
| FY 2024 | ₹169.82 | ₹59.16 | ₹83.54 | 44.5% |
| FY 2023 | ₹148.13 | ₹57.97 | ₹80.14 | 49.0% |
| FY 2022 | ₹114.19 | ₹43.62 | ₹62 | 49.5% |
Top companies in the same sector by market cap
| Company | Mkt Cap | P/E | ROCE | ROE | D/E | OPM |
|---|---|---|---|---|---|---|
| GUJTHEM ★ | — | 96.09 | 14.76% | 17.41% | 0.56x | 34.64% |
| SUNPHARMA | ₹4,27,609 Cr | 37.32 | 15.73% | 14.72% | 0.06x | 18.90% |
| CIPLA | ₹1,13,955 Cr | 33.87 | 13.66% | 11.74% | 0.02x | 12.55% |
| MAXHEALTH | ₹95,110 Cr | 66.21 | 11.94% | 14.33% | 0.32x | 22.56% |
| AUROPHARMA | ₹88,148 Cr | 25.39 | 12.55% | 9.93% | 0.21x | 15.11% |
| ASTERDM | ₹68,390 Cr | 104.34 | 8.93% | 10.07% | 0.46x | 13.98% |
All values in ₹ Crores
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total Assets | ₹301.31 | ₹221.11 | ₹166.33 | ₹122.5 |
| Equity | ₹248.38 | ₹201.38 | ₹149.15 | ₹103.32 |
| Total Debt | ₹30.47 | ₹2.77 | ₹0.42 | ₹1.17 |
| Cash | ₹11.69 | ₹6.47 | ₹6.05 | ₹0.26 |
| Net Debt | ₹18.2 | — | — | — |
| Working Capital | ₹31.41 | ₹31.4 | ₹46.45 | ₹61.23 |
Q1 FY2027
Quarter-over-Quarter Trend
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Q1 FY2027 | 71.98% ↑ | 0.65% ↓ | 0.53% ↓ | 26.84% ↑ |
| Q3 FY2026 | 70.87% | 1.96% ↓ | 1.17% | 26% ↑ |
| Q2 FY2026 | 70.87% | 2.95% ↑ | 1.17% | 25.01% ↓ |
| Q1 FY2026 | 70.87% | 2.51% ↑ | 1.17% | 25.44% ↓ |
| Q4 FY2025 | 70.87% | 1.91% ↑ | 1.17% | 26.05% ↓ |
| Q3 FY2025 | 70.87% | 1.42% ↓ | 1.17% | 26.55% ↑ |
| Q2 FY2025 | 70.87% | 1.49% ↑ | 1.17% ↓ | 26.47% ↓ |
| Q1 FY2025 | 70.87% | 1.44% | 1.18% | 26.52% |
No recent corporate actions
3 mutual fund schemes
Ask: "Is Gujarat Themis Biosyn Ltd stock a good buy right now?" — Get RSI, MACD, ROCE + AI recommendation
Analyse with OrionGet free stock analysis, market insights, and investment ideas delivered to your inbox.
No spam. Unsubscribe anytime.
Gujarat Themis Biosyn Ltd is listed on the NSE under the Healthcare sector, Pharmaceuticals industry. ISIN: INE942C01045. Track live share price, technical analysis, RSI, MACD, PE ratio, and smart money holdings on VestAI — India's AI-powered stock analysis platform.